Professur für Translationale Frauenheilkunde und Geburtshilfe

Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy (2023) Harbeck N, Kates R, Schinköthe T, Schumacher J, Wuerstlein R, Degenhardt T, Lüftner D, et al. Journal article, Review article Prevalence and course of pregnancy symptoms using self-reported pregnancy app symptom tracker data (2023) Nissen M, Barrios Campo N, Flaucher M, Jäger K, Titzmann A, Blunck D, Fasching P, et al. Journal article, Original article Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study (2023) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Journal article Predicting mammographic density with linear ultrasound transducers (2023) Behrens A, Fasching P, Schwenke E, Gaß P, Häberle L, Heindl F, Heusinger K, et al. Journal article Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant (2023) Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis (2023) Cortes J, Haiderali A, Huang M, Pan W, Schmid P, Akers KG, Park JE, et al. Journal article Association of two genomic variants with HPV type-specific risk of cervical cancer (2023) Seifert F, Eisenblätter R, Beckmann J, Schürmann P, Hanel P, Jentschke M, Böhmer G, et al. Journal article PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant (2023) Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, et al. Journal article Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy (2023) Huober J, van Mackelenbergh M, Schneeweiss A, Seither F, Blohmer JU, Denkert C, Tesch H, et al. Journal article Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry (2023) Mueller SH, Lai AG, Valkovskaya M, Michailidou K, Bolla MK, Wang Q, Dennis J, et al. Journal article